Multiple chronic conditions, older age or the Oxford/AstraZeneca vaccine might increase the need for a third dose
People with HIV with well-controlled viral load on antiretroviral treatment have similar levels of antibodies to HIV-negative people after two doses of a SARS-CoV-2 vaccine and in most cases will not need a third dose, Canadian researchers report.
However, they found that people who received two doses of the Oxford/Astra Zeneca vaccine had lower antibody levels after two doses compared to people who received other vaccines. Antibody levels were also lower in older people and those with multiple underlying health conditions.
The findings, from a study of 100 people with HIV and 152 HIV-negative controls in Vancouver, Canada, have been published as a pre-print article while it undergoes peer review.
Read the full story at Aidsmap.
Source : Aidsmap
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.